Skip to content
DataLookout
Menu

NCT07754461

A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 8 versions: 8 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 101 → 121 locations
  2. Minor Trial sites reduced: 121 → 101 locations
  3. Minor Study sites: 121 to 120
  4. Minor Site details revised at 26 of 121 sites
  5. Notable Eligibility criteria expanded, about 18 words
    • Secondary endpoints: details revised at 3 of 11 entries
    • Study sites revised (121)
  6. Minor Study sites: 120 to 121v3
  7. Notable Recruitment opened
    • Trial sites expanded: 115 → 120 locations
    v2
  8. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Absolute change in glycosylated haemoglobin A1c (HbA1c) (%) from baseline to Week 41
Timeframe: At baseline and Week 41.

Secondary (11)

Key secondary endpoint: Absolute change in HbA1c (%) from baseline to Week 53
Key secondary endpoint: Achievement of HbA1c <6.5% (yes/no) at Week 41
Achievement of HbA1c <5.7% (yes/no) at Week 41
Absolute change in fasting plasma glucose (mg/dL) from baseline to Week 53
Percent change in body weight (kg) from baseline to Week 53
Show 6 moreShow less
Relative change in non-HDL (high-density lipoprotein) cholesterol from baseline to Week 53
Relative change in triglycerides from baseline to Week 53
Estimated glomerular filtration rate (CKD-EPIcr) slope of change from baseline to Week 53
Relative change in urinary albumin-to-creatinine ratio (UACR) from baseline to Week 53 as a continuous variable
Absolute change in systolic blood pressure (SBP, mmHg) from baseline to Week 53
Part C: Absolute change in daily basal insulin dose from baseline to Week 53

Arms and interventions

Part A: PlaceboPlacebo comparator

Placebo as an add-on to diet and exercise.

Part A: Low-dose survodutideExperimental

Low-dose survodutide as an add-on to diet and exercise.

Part A: High-dose survodutideExperimental

High-dose survodutide as add-on to diet and exercise

Part B: PlaceboPlacebo comparator

Placebo as an add-on to anti-diabetic drugs.

Part B: Low-dose survodutideExperimental

Low-dose survodutide as an add-on to anti-diabetic drugs.

Part B: High-dose survodutideExperimental

High-dose survodutide as an add-on to anti-diabetic drugs.

Part C: PlaceboPlacebo comparator

Placebo as an add-on to basal insulin therapy with or without anti-diabetic drugs.

Part C: Low-dose survodutideExperimental

Low-dose as an add-on to basal insulin therapy with or without anti-diabetic drugs.

Part C: High-dose survodutideExperimental

High-dose as an add-on to basal insulin therapy with or without anti-diabetic drugs.

Drugs: Placebo, Survodutide

Sites

121 sites in 6 countries

United States 90, India 13, Canada 10, Australia 4, New Zealand 3, Puerto Rico 1